Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

DYRK1A inhibitors for disease therapy: Current status and perspectives
Tong Liu, Yuxi Wang, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 229, pp. 114062-114062
Closed Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy
Yun Liu, Yang Li, Yuxi Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 97
Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 51
Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects
Yijia Chen, Yuxi Wang, Jiaxing Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2257-2281
Closed Access | Times Cited: 39
Targeting EZH2 for cancer therapy: From current progress to novel strategies
Jia Zeng, Jifa Zhang, Ying Sun, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114419-114419
Closed Access | Times Cited: 63
Polo-like Kinase 1 Inhibitors in Human Cancer Therapy: Development and Therapeutic Potential
Jifa Zhang, Lele Zhang, Jiaxing Wang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 15, pp. 10133-10160
Closed Access | Times Cited: 59
Targeting ferroptosis: Paving new roads for drug design and discovery
Yilin Gu, Yizhe Li, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 247, pp. 115015-115015
Closed Access | Times Cited: 48
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Yingxu Fang, Jiaxing Wang, Min Zhao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 17, pp. 11454-11477
Closed Access | Times Cited: 45
Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases
Mattias F. Lindberg, Emmanuel Deau, Jonas Arfwedson, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 4106-4130
Closed Access | Times Cited: 25
Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles
Li Chen, Wuyu Mao, Changyu Ren, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 1, pp. 38-64
Closed Access | Times Cited: 11
ncRNAs and their impact on dopaminergic neurons: Autophagy pathways in Parkinson's disease
Riya Thapa, Ehssan Moglad, Muhammad Afzal, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102327-102327
Closed Access | Times Cited: 11
The Omnipresence of DYRK1A in Human Diseases
Estelle Deboever, Alessandra Fistrovich, Christopher Hulme, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9355-9355
Open Access | Times Cited: 33
Medicinal chemistry strategies targeting PRMT5 for cancer therapy
Siyu Fu, Qinwen Zheng, Dan Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114842-114842
Closed Access | Times Cited: 27
Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics
Jiayu Wang, Jifa Zhang, Jiaxing Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 10, pp. 6437-6462
Closed Access | Times Cited: 18
Development and therapeutic potential of adaptor-associated kinase 1 inhibitors in human multifaceted diseases
Xin Xin, Yue Wang, Lele Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 248, pp. 115102-115102
Closed Access | Times Cited: 17
Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives
Zhendong Niu, Peng Lei, Yuxi Wang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 253, pp. 115326-115326
Closed Access | Times Cited: 16
Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges
Ruofei Zhang, Yuxi Wang, Aijia Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115658-115658
Closed Access | Times Cited: 16
EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model
Jean Maurice Delabar, Marco Antônio G. B. Gomes, Marta Fructuoso, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116098-116098
Closed Access | Times Cited: 6
Pancreatic β-cell failure, clinical implications, and therapeutic strategies in type 2 diabetes
Daxin Cui, Xingrong Feng, Si-Man Lei, et al.
Chinese Medical Journal (2024) Vol. 137, Iss. 7, pp. 791-805
Open Access | Times Cited: 5
Application of a macrocyclization strategy in kinase inhibitor development
Kun Xing, Shujun Li, Jing Li, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 1
Open Access
Critical review on biological effects and mechanisms of amide alkaloids in Piper nigrum and Piper longum
Guang-Ju Gu, Yu Yang, Feng Zhang, et al.
Food & medicine homology. (2025)
Closed Access
From Dyrk1A inhibitors to a novel class of antiviral agents: Targeting Enterovirus EV-A71 with 2-aryl-substituted thiophene scaffolds
Parthiena M Keddis, Tuong-Khanh My Tu, Hugo Scherer, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117348-117348
Closed Access
Towards Imaging Tau Hyperphosphorylation: Is DYRK1A a Potential Target for Imaging Hyperphosphorylation of Tau? Molecular Modeling Assessment and Synthesis of [125I]Radioiodinated DYRK1A Inhibitor
Cayz G. Paclibar, Danielle Schafer, Agnes P. Biju, et al.
Molecules (2025) Vol. 30, Iss. 5, pp. 990-990
Open Access
Eriodictyol inhibits the proliferation and inflammatory response in keratinocytes in psoriasis through inactivating DYRK1A-mediated endoplasmic reticulum stress
Yuan Rui, Qi-Chao Sun, Yuepeng An, et al.
Journal of Asian Natural Products Research (2025), pp. 1-13
Closed Access
Unlocking the Therapeutic Potential of the Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitors in Alzheimer’s Diseases
Dipanjan Karati, Shreyasi Meur, Ankur Saha, et al.
Molecular Neurobiology (2025)
Closed Access
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy
Ya Zhang, Zelin Hu, Jifa Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114524-114524
Closed Access | Times Cited: 26
Page 1 - Next Page

Scroll to top